All Stories

  1. La GTPase RhoB, un nouvel acteur de la résistance adaptative aux inhibiteurs de la tyrosine kinase du récepteur de l'EGF dans les cancers du poumon

    Article • médecine/sciences, January 2018, EDP Sciences

    Professor Gilles Favre

  2. SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction

    Article • BMC Cancer, August 2015, Springer Science + Business Media

    Professor Gilles Favre

  3. In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression

    Article • Frontiers in Oncology, July 2015, Frontiers

    Professor Gilles Favre

  4. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors

    Article • Oncotarget, June 2015, Impact Journals, LLC

    Professor Gilles Favre

  5. Abstract P4-07-08: Circulating miRNAs as surrogate markers for hormonosensibility in patients with hormone receptor-positive metastatic breast cancer? A pilot study

    Article • Cancer Research, April 2015, American Association for Cancer Research (AACR)

    Professor Gilles Favre

  6. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study

    Article • BMC Medical Genomics, January 2015, Springer Science + Business Media

    Professor Gilles Favre, Dr Thomas Filleron

  7. Targeted Identification of Sialoglycoproteins in Hypoxic Endothelial Cells and Validation in Zebrafish Reveal Roles for Proteins in Angiogenesis

    Article • Journal of Biological Chemistry, November 2014, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Gilles Favre

  8. Generation of a Single Chain Antibody Variable Fragment (scFv) to Sense Selectively RhoB Activation

    Article • PLoS ONE, November 2014, PLOS

    Professor Gilles Favre

  9. Contribution des responsables des Cancéropôles au Forum/Débat sur le bilan des actions des Cancéropôles

    Article • médecine/sciences, October 2014, EDP Sciences

    Professor Gilles Favre

  10. Abstract 5524: 5-aza-2′-deoxycytidine, a DNA demethylating agent, inhibits metastatic melanoma invasiveness

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Professor Gilles Favre

  11. Abstract 1865: Circulating microRNA expression profile: miR-1246 and miR-185 profile as a novel diagnostic biomarker for melanoma

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Professor Gilles Favre

  12. RhoB Promotes γH2AX Dephosphorylation and DNA Double-Strand Break Repair

    Article • Molecular and Cellular Biology, June 2014, ASM Journals

    Professor Gilles Favre

  13. RhoB Promotes Cancer Initiation by Protecting Keratinocytes from UVB-Induced Apoptosis but Limits Tumor Aggressiveness

    Article • Journal of Investigative Dermatology, January 2014, Elsevier

    Professor Gilles Favre, Dr Thomas Filleron

  14. A New Protein-Protein Interaction Sensor Based on Tripartite Split-GFP Association

    Article • Scientific Reports, October 2013, Springer Science + Business Media

    Professor Gilles Favre, Dr Stephanie Cabantous

  15. Symbolic Data Analysis to Defy Low Signal-to-Noise Ratio in Microarray Data for Breast Cancer Prognosis

    Article • Journal of Computational Biology, August 2013, Mary Ann Liebert Inc

    Professor Gilles Favre

  16. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma

    Article • European Journal of Cancer, June 2013, Elsevier

    Professor Gilles Favre, Dr Thomas Filleron

  17. Abstract 3401: Vemurafenib-induced RhoB expression leads to melanoma cell resistance.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Professor Gilles Favre

  18. RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor

    Article • January 2013, Springer Science + Business Media

    Professor Gilles Favre, Dr Thomas Filleron

  19. Statins Reduce Melanoma Development and Metastasis through MICA Overexpression

    Article • Frontiers in Immunology, January 2013, Frontiers

    Professor Gilles Favre

  20. Characteristics of lung cancer in women: Importance of hormonal and growth factors

    Article • Lung Cancer, June 2012, Elsevier

    Professor Gilles Favre

  21. Single domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naïve libraries

    Article • Developmental & Comparative Immunology, January 2012, Elsevier

    Professor Gilles Favre, Dr Thomas Filleron

  22. Use of Phage Display for the Identification of Molecular Sensors Specific for Activated Rho

    Article • November 2011, Springer Science + Business Media

    Professor Gilles Favre

  23. Abstract 2225: First double validation of transcription infidelity biomarkers for breast cancer diagnosis

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Professor Gilles Favre

  24. Abstract 2049: Post transcriptional regulation of RhoB expression

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Professor Gilles Favre

  25. Melanoma Cells Treated with GGTI and IFN-γ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells

    Article • PLoS ONE, February 2010, PLOS

    Professor Gilles Favre

  26. Preferential Transfer of Certain Plasma Membrane Proteins onto T and B Cells by Trogocytosis

    Article • PLoS ONE, January 2010, PLOS

    Professor Gilles Favre

  27. Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2009, Elsevier

    Professor Gilles Favre

  28. A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer

    Article • Breast Cancer Research and Treatment, September 2009, Springer Science + Business Media

    Professor Gilles Favre

  29. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding

    Article • Breast Cancer Research and Treatment, April 2009, Springer Science + Business Media

    Professor Gilles Favre

  30. Oncologic Trogocytosis of an Original Stromal Cells Induces Chemoresistance of Ovarian Tumours

    Article • PLoS ONE, December 2008, PLOS

    Professor Gilles Favre

  31. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization

    Article • Experimental Cell Research, September 2008, Elsevier

    Professor Gilles Favre

  32. αvβ3 and αvβ5 integrins control glioma cell response to ionising radiation through ILK and RhoB

    Article • International Journal of Cancer, May 2008, Wiley

    Professor Gilles Favre

  33. Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection

    Article • BMC Biotechnology, March 2008, Springer Science + Business Media

    Professor Gilles Favre

  34. Statins Stimulate In Vitro Membrane FasL Expression and Lymphocyte Apoptosis through RhoA/ROCK Pathway in Murine Melanoma Cells

    Article • Neoplasia, December 2007, Elsevier

    Professor Gilles Favre

  35. Epigenetic regulation of RhoB loss of expression in lung cancer

    Article • BMC Cancer, November 2007, Springer Science + Business Media

    Professor Gilles Favre

  36. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity

    Article • Cancer Gene Therapy, June 2005, Springer Science + Business Media

    Professor Gilles Favre

  37. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells

    Article • Experimental Cell Research, April 2005, Elsevier

    Professor Gilles Favre

  38. Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study

    Article • Current Medicinal Chemistry - Anti-Cancer Agents, November 2004, Bentham Science Publishers

    Professor Gilles Favre

  39. Pharmacological-based translational induction of transgene expression in mammalian cells

    Article • EMBO Reports, July 2004, EMBO

    Professor Gilles Favre

  40. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules

    Article • Cancer Gene Therapy, May 2004, Springer Science + Business Media

    Professor Gilles Favre

  41. Perspectives on farnesyl transferase inhibitors in cancer therapy

    Article • Cancer Letters, April 2004, Elsevier

    Professor Gilles Favre

  42. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12

    Article • Journal of Gastroenterology and Hepatology, April 2004, Wiley

    Professor Gilles Favre

  43. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts

    Article • Oncogene, December 2003, Springer Science + Business Media

    Professor Gilles Favre

  44. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression

    Article • International Journal of Cancer, July 2003, Wiley

    Professor Gilles Favre

  45. Cloning of the human RHOB gene promoter: characterization of a VNTR sequence that affects transcriptional activity

    Article • Genomics, May 2003, Elsevier

    Professor Gilles Favre

  46. Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells

    Article • Endocrinology, March 2003, Endocrine Society

    Professor Gilles Favre, Dr Marc Etienne Poirot

  47. Les inhibiteurs de farnésyl transférase : une cible peut en cacher une autre

    Article • médecine/sciences, February 2003, EDP Sciences

    Professor Gilles Favre

  48. Farnesylated RhoB Prevents Cell Cycle Arrest and Actin Cytoskeleton Disruption Caused by the Geranylgeranyltransferase I Inhibitor GGTI-298

    Article • Cell Cycle, November 2002, Taylor & Francis

    Professor Gilles Favre

  49. The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit

    Article • Oncogene, September 2002, Springer Science + Business Media

    Professor Gilles Favre

  50. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death

    Article • Oncogene, September 2002, Springer Science + Business Media

    Professor Gilles Favre

  51. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells

    Article • International Journal of Cancer, July 2002, Wiley

    Professor Gilles Favre

  52. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation

    Article • International Journal of Cancer, May 2002, Wiley

    Professor Gilles Favre

  53. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells

    Article • Cancer Gene Therapy, March 2002, Springer Science + Business Media

    Professor Gilles Favre

  54. Inhibition of human tumor cell growthin vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228

    Article • International Journal of Cancer, January 2001, Wiley

    Professor Gilles Favre

  55. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

    Article • Cancer Gene Therapy, December 2000, Springer Science + Business Media

    Professor Gilles Favre

  56. Inhibition of human tumor cell growthIn vitro andIn vivo by a specific inhibitor of human farnesyltransferase: BIM-46068

    Article • International Journal of Cancer, October 1999, Wiley

    Professor Gilles Favre

  57. The Farnesyltransferase Inhibitor FTI-277 Suppresses the 24-kDa FGF2-Induced Radioresistance in HeLa Cells Expressing Wild-Type RAS

    Article • Radiation Research, October 1999, JSTOR

    Professor Gilles Favre

  58. Epidermal Growth Factor Stimulates 3-Hydroxy-3-Methylglutaryl-coenzyme A Reductase Expression via the ErbB-2 Pathway in Human Breast Adenocarcinoma Cells

    Article • Biochemical and Biophysical Research Communications, July 1999, Elsevier

    Professor Gilles Favre

  59. Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells

    Article • Biochemical Journal, February 1998, Portland Press Ltd.

    Professor Gilles Favre

  60. Preferential Cytoplasmic Localization of p34 cdc2 in Recurrent Human Squamous Cell Carcinoma after Radiotherapy

    Article • Radiation Research, March 1997, JSTOR

    Professor Gilles Favre

  61. Oxidative damage on RNA mediated by cationic metalloporphyrin–antisense oligonucleotides conjugates †

    Article • Journal of the Chemical Society Dalton Transactions, January 1997, Royal Society of Chemistry

    Professor Gilles Favre

  62. Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular BioVector (SMBV)

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, January 1997, Elsevier

    Professor Gilles Favre

  63. Farnesol and Geranylgeraniol Induce Actin Cytoskeleton Disorganization and Apoptosis in A549 Lung Adenocarcinoma Cells

    Article • Biochemical and Biophysical Research Communications, August 1996, Elsevier

    Professor Gilles Favre

  64. A new family of potential oncostatics: 2-chloroethylnitrososulfamides (CENS)—I. Synthesis, structure, and pharmacological evaluation (preliminary results)

    Article • Bioorganic & Medicinal Chemistry, August 1996, Elsevier

    Professor Gilles Favre

  65. Indium-111 Labeling of Low Density Lipoproteins with the DTPA−Bis(stearylamide):  Evaluation as a Potential Radiopharmaceutical for Tumor Localization

    Article • Bioconjugate Chemistry, January 1996, American Chemical Society (ACS)

    Professor Gilles Favre

  66. Synthesis and characterization of supramolecular biovector (SMBV) specifically designed for the entrapment of ionic molecules

    Article • Biochimica et Biophysica Acta (BBA) - Biomembranes, July 1995, Elsevier

    Professor Gilles Favre

  67. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line a549

    Article • International Journal of Cancer, October 1993, Wiley

    Professor Gilles Favre

  68. Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug-LDL complex via the LDL receptor pathway in vitro

    Article • Biochemical Pharmacology, July 1990, Elsevier

    Professor Gilles Favre

  69. Proliferative effect of high density lipoprotein (HDL) and HDL fractions (HDL1,2, HDL3) on virus transformed lymphoblastoid cells

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, September 1989, Elsevier

    Professor Gilles Favre

  70. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro

    Article • European Journal of Cancer and Clinical Oncology, February 1989, Elsevier

    Professor Gilles Favre

  71. Evidence for qualitative abnormalities in high-density lipoproteins from myeloma patients: The presence of amyloid A protein could explain HDL modifications

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, November 1988, Elsevier

    Professor Gilles Favre

  72. Mitogenic Effect of High Density Lipoprotein (HDL) on Lymphoblastoid Cells Involved HMG-CoA Reductase Activity

    Article • January 1988, Springer Science + Business Media

    Professor Gilles Favre

  73. Serum Apolipoproteins A-I, A-II and B in Hepatic Metastases Comparison with other Liver Diseases: Hepatomas and Cirrhosis

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1986, De Gruyter

    Professor Gilles Favre

  74. Prenyltransferase Inhibitors as Radiosensitizers

    Article • Springer Science + Business Media

    Professor Gilles Favre